Beyond Purely Data-Driven Approaches for Efficient Knowledge Management in Process Development


02nd September 2019 | 10:00 am CEST | Moritz von Stosch, PhD, Senior Manager, Technical R&D, GlaxoSmithKline Vaccines and Klaus Mauch, CEO at Insilico Biotechnology AG |BOOK FREE SEAT

Knowledge from first principles is freely available and generally valid, and when integrated along with Artificial Intelligence (data-driven) methods, it can greatly improve the understanding and applicability. The applications of such an approach, referred to as hybrid modelling, to a fermentation and controlled drug release case are presented and the learnings from the development of these models are shared.

Presented by Moritz von Stosch, PhD, Senior Manager, Technical R&D, GlaxoSmithKline Vaccines

Moritz von Stosch works as Senior Manager at Technical R&D of GSK Biologicals, Belgium. He is a process systems engineer by education with a Diplom in Chemical Engineering from the RWTH-Aachen University and PhD in Biochemical Engineering from the University of Porto. Before joining GSK, Moritz worked as a Lecturer at the School of Chemical Engineering and Advanced Materials at Newcastle University, where his research focused on the development of novel hybrid modeling methods and their application to enable more efficient process operation/design.

And Klaus Mauch, CEO at Insilico Biotechnology AG

Klaus Mauch is one of Insilico’s co-founders and became managing director in 2004 and CEO in 2006. In his previous role as CTO, he was responsible for the design and development of Insilico’s modelling and simulation platform where he established novel methods for the computer-aided construction of cellular networks. Before that, he gained extensive experience in metabolic engineering and applied systems biology as a group leader at the Institute of Biochemical Engineering, University of Stuttgart. He was awarded a Master’s degree in Chemical Engineering by the Technical University of Karlsruhe, Germany. Klaus is a member of the Advisory Board of the Division Systems Biology and Synthetic Biology of DECHEMA, board member of the Industrial Association White Biotechnology (IWBio), and board member of the Association of German Biotechnology Companies (VBU).

Sponsored by Insilico Biotechnology AG

Insilico Biotechnology is a market-leader in providing solutions and software for the simulation of living cells. The company has two main areas of operation, Biotechnological Process Optimisation and Software Engineering.

Insilico’s experts use the company’s proprietary software tools, databases and high performance computing facilities to analyse the latest cellular data – such as metabolite data, transcript data and proteome data – and integrate it in mechanistic, genome-based cell and organ models.

For many global-leading companies from chemical and pharmaceutical sectors, Insilico’s technology already lowers the time, costs and risks involved in their development processes.

Successful in business since 2001, Insilico continues to consolidate its competitive advantage by providing new insights in its operating fields and generating novel IP for its customers.

Insilico is a privately owned company, based in Stuttgart, Germany.


We will not sell your information to a third party. See our Privacy Policy